Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the Horse

被引:64
作者
Kenderian, Saad S. [1 ,2 ]
Porter, David L. [3 ,4 ]
Gill, Saar [1 ,3 ,4 ]
机构
[1] Univ Penn, Ctr Cellular Immunotherapies, Philadelphia, PA 19104 USA
[2] Mayo Clin, Dept Med, Div Hematol, Rochester, MN USA
[3] Univ Penn, Sch Med, Div Hematol Oncol, Philadelphia, PA 19104 USA
[4] Univ Penn, Sch Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA
关键词
Chimeric antigen receptor; T cells; CART19; Immunotherapy; Adoptive T cell therapy; Adoptive immunotherapy; Hematopoietic stem cell transplantation; Bone marrow transplantation; ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; NON-HODGKIN-LYMPHOMA; B-CELL; ANTITUMOR-ACTIVITY; CYTOKINE RELEASE; ADOPTIVE IMMUNOTHERAPY; THERAPY; EFFICACY; CD8(+);
D O I
10.1016/j.bbmt.2016.09.002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Hematopoietic cell transplantation (HCT) remains an important and potentially curative option for most hematologic malignancies. As a form of immunotherapy, allogeneic HCT (allo-HCT) offers the potential for durable remissions but is limited by transplantation- related morbidity and mortality owing to organ toxicity, infection, and graft-versus-host disease. The recent positive outcomes of chimeric antigen receptor T (CART) cell therapy in B cell malignancies may herald a paradigm shift in the management of these disorders and perhaps other hematologic malignancies as well. Clinical trials are now needed to address the relative roles of CART cells and HCT in the context of transplantation-eligible patients. In this review, we summarize the state of the art of the development of CART cell therapy for leukemia, lymphoma, and myeloma and discuss our perspective of how CART cell therapy can be applied in the context of HCT. (C) 2017 American Society for Blood and Marrow Transplantation.
引用
收藏
页码:235 / 246
页数:12
相关论文
共 101 条
[11]  
[Anonymous], 2015, BLOOD
[12]   Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy [J].
Barrett, David M. ;
Singh, Nathan ;
Liu, Xiaojun ;
Jiang, Shuguang ;
June, Carl H. ;
Grupp, Stephan A. ;
Zhao, Yangbing .
CYTOTHERAPY, 2014, 16 (05) :619-630
[13]   Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies [J].
Beatty, Gregory L. ;
Haas, Andrew R. ;
Maus, Marcela V. ;
Torigian, Drew A. ;
Soulen, Michael C. ;
Plesa, Gabriela ;
Chew, Anne ;
Zhao, Yangbing ;
Levine, Bruce L. ;
Albelda, Steven M. ;
Kalos, Michael ;
June, Carl H. .
CANCER IMMUNOLOGY RESEARCH, 2014, 2 (02) :112-120
[14]   Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15 [J].
Brentjens, RJ ;
Latouche, JB ;
Santos, E ;
Marti, F ;
Gong, MC ;
Lyddane, C ;
King, PD ;
Larson, S ;
Weiss, M ;
Rivière, I ;
Sadelain, M .
NATURE MEDICINE, 2003, 9 (03) :279-286
[15]   Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease [J].
Brudno, Jennifer N. ;
Somerville, Robert P. T. ;
Shi, Victoria ;
Rose, Jeremy J. ;
Halverson, David C. ;
Fowler, Daniel H. ;
Gea-Banacloche, Juan C. ;
Pavletic, Steven Z. ;
Hickstein, Dennis D. ;
Lu, Tangying L. ;
Feldman, Steven A. ;
Iwamoto, Alexander T. ;
Kurlander, Roger ;
Maric, Irina ;
Goy, Andre ;
Hansen, Brenna G. ;
Wilder, Jennifer S. ;
Blacklock-Schuver, Bazetta ;
Hakim, Frances T. ;
Rosenberg, Steven A. ;
Gress, Ronald E. ;
Kochenderfer, James N. .
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (10) :1112-+
[16]   Allogeneic T-Cells Expressing an Anti-CD19 Chimeric Antigen Receptor Cause Remissions of B-Cell Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation without Causing Graft-Versus-Host Disease [J].
Brudno, Jennifer N. ;
Somerville, Robert ;
Shi, Victoria ;
Rose, Jeremy J. ;
Halverson, David C. ;
Fowler, Daniel H. ;
Hickstein, Dennis D. ;
Gea-Banacloche, Juan C. ;
Pavletic, Steven Z. ;
Goy, Andre ;
Lu, Tangying L. ;
Feldman, Steven ;
Iwamoto, Alex ;
Kurlander, Roger ;
Maric, Irina ;
Hansen, Brenna ;
Wilder, Jennifer S. ;
Blacklock-Shuver, Bazetta ;
Hakim, Frances T. ;
Rosenberg, Steven A. ;
Gress, Ronald E. ;
Kochenderfer, James N. .
BLOOD, 2015, 126 (23)
[17]   Ligation of the CD2 co-stimulatory receptor enhances IL-2 production from first-generation chimeric antigen receptor T cells [J].
Cheadle, E. J. ;
Rothwell, D. G. ;
Bridgeman, J. S. ;
Sheard, V. E. ;
Hawkins, R. E. ;
Gilham, D. E. .
GENE THERAPY, 2012, 19 (11) :1114-1120
[18]   CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma [J].
Chu, J. ;
Deng, Y. ;
Benson, D. M. ;
He, S. ;
Hughes, T. ;
Zhang, J. ;
Peng, Y. ;
Mao, H. ;
Yi, L. ;
Ghoshal, K. ;
He, X. ;
Devine, S. M. ;
Zhang, X. ;
Caligiuri, M. A. ;
Hofmeister, C. C. ;
Yu, J. .
LEUKEMIA, 2014, 28 (04) :917-927
[19]   Multiplex Genome Engineering Using CRISPR/Cas Systems [J].
Cong, Le ;
Ran, F. Ann ;
Cox, David ;
Lin, Shuailiang ;
Barretto, Robert ;
Habib, Naomi ;
Hsu, Patrick D. ;
Wu, Xuebing ;
Jiang, Wenyan ;
Marraffini, Luciano A. ;
Zhang, Feng .
SCIENCE, 2013, 339 (6121) :819-823
[20]   Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia [J].
Davila, Marco L. ;
Riviere, Isabelle ;
Wang, Xiuyan ;
Bartido, Shirley ;
Park, Jae ;
Curran, Kevin ;
Chung, Stephen S. ;
Stefanski, Jolanta ;
Borquez-Ojeda, Oriana ;
Olszewska, Malgorzata ;
Qu, Jinrong ;
Wasielewska, Teresa ;
He, Qing ;
Fink, Mitsu ;
Shinglot, Himaly ;
Youssif, Maher ;
Satter, Mark ;
Wang, Yongzeng ;
Hosey, James ;
Quintanilla, Hilda ;
Halton, Elizabeth ;
Bernal, Yvette ;
Bouhassira, Diana C. G. ;
Arcila, Maria E. ;
Gonen, Mithat ;
Roboz, Gail J. ;
Maslak, Peter ;
Douer, Dan ;
Frattini, Mark G. ;
Giralt, Sergio ;
Sadelain, Michel ;
Brentjens, Renier .
SCIENCE TRANSLATIONAL MEDICINE, 2014, 6 (224)